Becton Dickinson closes GenOhm acquisition:
This article was originally published in Clinica
Becton Dickinson (BD) has completed its acquisition of GeneOhm Sciences, the San Diego, California-based developer of rapid DNA tests for bacterial organisms. BD, of Franklin Lakes, New Jersey, agreed to buy GeneOhm in January for $230m, as well as additional incentives of up to $25m. GeneOhm's technologies include tests that detect bacteria known to cause healthcare-associated infections (HAIs).
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.